美国对治疗阿片类药物和酒精上瘾的基于遗传的药物取得专利。 Adial Pharmaceuticals earns U.S. patent for a genetic-based drug treating opioid and alcohol addiction.

Adial制药公司获得了美国对类阿片和酒精使用紊乱进行基于遗传的治疗的新专利。 Adial Pharmaceuticals received a new U.S. patent for a genetic-based treatment of opioid and alcohol use disorders. 专利涵盖他们的药物AD04,该药物是专门为患有与药物使用失调有关的具体遗传标记的病人量身定制的。 The patent covers their drug, AD04, which is tailored for patients with specific genetic markers linked to substance use disorders. 这一方法旨在改善那些对传统疗法反应不佳的人的治疗结果。 This approach aims to improve treatment outcomes for those who do not respond well to traditional therapies. 该公司还完成了一项研究,确认AD04的安全性,并计划最后完成第3阶段试验设计,供林业发展局批准。 The company has also completed a study confirming AD04's safety and plans to finalize Phase 3 trial design for FDA approval.